Tranexamic Acid and Sublingual Misoprostol Efficacy Compared for Cesarean Section Blood Loss Reduction

Excessive blood loss during and after Cesarean section (CS), particularly postpartum hemorrhage (PPH), remains a leading cause of maternal morbidity and mortality worldwide. High-risk pregnancies, often complicated by conditions like placenta previa, multiple gestations, or pre-existing coagulopathies, further elevate this risk. Current prophylactic strategies, including uterotonic agents, aim to minimize blood loss, but their efficacy and safety profiles can vary. There is a continuous need to identify optimal interventions that can significantly reduce blood loss and improve outcomes for these vulnerable patients, prompting comparative studies of established agents like tranexamic acid and misoprostol.

This study was designed as a comparative trial to assess the efficacy and safety of two prophylactic agents in high-risk pregnant cases undergoing elective CS. Participants were randomized to receive either 1 gm intravenous Tranexamic acid diluted in 20 ml of Glucose 5% (administered as an IV infusion over 5 minutes, at least 15 minutes prior to skin incision) or sublingual misoprostol. The primary endpoints included the quantification of blood loss during and after the elective Cesarean section. Secondary endpoints focused on safety, specifically monitoring for adverse events associated with each treatment arm. The study aimed to provide a direct comparison of these two interventions in a clinically relevant population.

The study was designed to rigorously compare the effects of Tranexamic acid and sublingual misoprostol on various blood loss parameters. Researchers aimed to quantify differences in total intraoperative and postoperative blood loss, typically measured in milliliters, and assess the need for additional uterotonic agents or blood transfusions. Safety endpoints included the incidence of adverse events, such as nausea, vomiting, fever, or thromboembolic complications, which are critical considerations for both interventions. The primary objective was to determine if one agent offered a statistically significant advantage in reducing blood loss or improving the safety profile for high-risk patients. While the abstract outlines these comprehensive objectives and the comparative design, it does not present specific numerical results, p-values, or effect sizes for blood loss reduction, transfusion rates, or adverse event occurrences. Therefore, conclusions regarding the comparative efficacy or safety of Tranexamic acid versus sublingual misoprostol cannot be drawn from the provided information.